Lung cancer drugs may stress the heart – new study investigates

NCT ID NCT07267247

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 100 people with advanced EGFR-mutant lung cancer who were taking drugs called EGFR-TKIs (erlotinib, dacomitinib, afatinib, or osimertinib). The goal was to see how often these drugs cause heart problems, specifically a drop in the heart's pumping ability. Researchers measured heart function before and during treatment to track any changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
EGFR-TKI drugs (erlotinib, dacomitinib, afatinib, osimertinib)
What this could lead to
If successful, this could help doctors better monitor and prevent heart side effects in lung cancer patients taking these drugs.
What could go wrong
This is a small, single-center observational study, so results may not apply to all patients. It only measures heart function changes, not whether these changes cause symptoms or affect survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Taichung Veterans General Hospital

    Taichung, 407, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.